Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma (Q33394324)

26 July 2017

title

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma (English)

1 reference

peripheral T-cell lymphoma

26 July 2017

main subject

phase II clinical trial

0 references

1 reference

Steven L Allen

6

0 references

Elaine Jaffe

object named as

Elaine S Jaffe

7

0 references

Susan E Bates

20

object named as

Susan E Bates

1 reference

26 July 2017

18

A Tito Fojo

1 reference

William Douglas Figg, Sr.

26 July 2017

11

object named as

William D Figg

1 reference

26 July 2017

12

Seth M Steinberg

1 reference

26 July 2017

1

Richard L Piekarz

1 reference

26 July 2017

Robin Frye

2

1 reference

26 July 2017

H Miles Prince

3

1 reference

26 July 2017

Mark H Kirschbaum

4

1 reference

26 July 2017

Jasmine Zain

5

1 reference

26 July 2017

Alexander Ling

8

1 reference

26 July 2017

Maria Turner

9

1 reference

26 July 2017

Cody J Peer

10

1 reference

26 July 2017

Sonali Smith

13

1 reference

26 July 2017

David Joske

14

1 reference

26 July 2017

Ian Lewis

15

1 reference

26 July 2017

Laura Hutchins

16

1 reference

26 July 2017

Michael Craig

17

1 reference

26 July 2017

John J Wright

19

1 reference

26 July 2017

language of work or name

English

0 references

publication date

25 February 2011

1 reference

26 July 2017

number of pages

8

1 reference

inferred from page(s)

published in

Blood

1 reference

26 July 2017

volume

117

1 reference

26 July 2017

issue

22

1 reference

26 July 2017

page(s)

5827-5834

1 reference

Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

Clinical studies of histone deacetylase inhibitors.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

A review of depsipeptide and other histone deacetylase inhibitors in clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

Optimal two-stage designs for phase II clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

Epigenetic modifiers: basic understanding and clinical development.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112033

Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21355097

12 December 2020

inferred from PubMed ID database lookup

Challenges of evaluating the cardiac effects of anticancer agents

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21355097

12 December 2020

inferred from PubMed ID database lookup

Clinical Toxicities of Histone Deacetylase Inhibitors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21355097

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1182/BLOOD-2010-10-312603

1 reference

release_2a7claushjhahgnbu3xo2c63ga

26 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2a7claushjhahgnbu3xo2c63ga

24 November 2022

mapped directly with Wikidata item

PMC publication ID

3112033

1 reference

26 July 2017

1 reference